- Home
- SOPA vs ATXI Comparison
SOPA vs ATXI Comparison
Compare SOPA & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPA
- ATXI
- Stock Information
- Founded
- SOPA 2018
- ATXI 2015
- Country
- SOPA Singapore
- ATXI United States
- Employees
- SOPA N/A
- ATXI N/A
- Industry
- SOPA EDP Services
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- SOPA Technology
- ATXI Health Care
- Exchange
- SOPA Nasdaq
- ATXI Nasdaq
- Market Cap
- SOPA 3.5M
- ATXI 3.0M
- IPO Year
- SOPA 2021
- ATXI 2017
- Fundamental
- Price
- SOPA $0.83
- ATXI $1.70
- Analyst Decision
- SOPA Buy
- ATXI
- Analyst Count
- SOPA 2
- ATXI 0
- Target Price
- SOPA $16.00
- ATXI N/A
- AVG Volume (30 Days)
- SOPA 29.9K
- ATXI 22.1K
- Earning Date
- SOPA 11-15-2024
- ATXI 11-14-2024
- Dividend Yield
- SOPA N/A
- ATXI N/A
- EPS Growth
- SOPA N/A
- ATXI N/A
- EPS
- SOPA N/A
- ATXI N/A
- Revenue
- SOPA $6,906,240.00
- ATXI N/A
- Revenue This Year
- SOPA $14.21
- ATXI N/A
- Revenue Next Year
- SOPA $98.91
- ATXI N/A
- P/E Ratio
- SOPA N/A
- ATXI N/A
- Revenue Growth
- SOPA N/A
- ATXI N/A
- 52 Week Low
- SOPA $0.73
- ATXI $1.60
- 52 Week High
- SOPA $5.10
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- SOPA 42.29
- ATXI 30.21
- Support Level
- SOPA $0.82
- ATXI $1.80
- Resistance Level
- SOPA $0.95
- ATXI $1.88
- Average True Range (ATR)
- SOPA 0.07
- ATXI 0.11
- MACD
- SOPA -0.01
- ATXI -0.02
- Stochastic Oscillator
- SOPA 35.91
- ATXI 0.00
About SOPA Society Pass Incorporated
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with visionary entrepreneurs, the company meets the growing demand for better services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food and grocery deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Merchant Point of Sale (merchant POS). The company generates the majority of its revenue from the Digital marketing segment.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.